Image of OraQuick Rapid HIV-1 Test and OraSure Technologies Logo

NOTE TO MEDIA: Multimedia assets available

A photo is available at URL:

http://www.businesswire.com/cgi-bin/photo.cgi?pw.110702/bb12

BETHLEHEM, Pa.--(BUSINESS WIRE)--Nov. 7, 2002--OraSure Technologies, Inc. (Nasdaq:OSUR), the market leader in oral fluid diagnostics, announced today that it has received approval from the U.S. Food and Drug Administration ("FDA") for its OraQuick(R) Rapid HIV-1 Antibody Test. Pursuant to this approval, the Company can manufacture and market the OraQuick(R) test in the United States for the detection of HIV-1 antibodies in finger-stick whole blood samples.

A full release was posted on Business Wire at 1:05 pm EST today.

--30--des/ph*